Lorlatinib
Use attributes for filter ! | |
Bioavailability | 81% |
---|---|
Formula | C21H19FN6O2 |
Trade name | Lorbrena, Lorviqua |
Other names | PF-6463922 |
ATC code | L01XE44 (WHO) |
Elimination half-life | 24 hrs (single dose) |
Music groups | Brigatinib |
Alectinib | |
Ceritinib | |
Crizotinib | |
Date of Reg. | |
Date of Upd. | |
ID | 2951232 |
About Lorlatinib
Lorlatinib, sold under the brand name Lorbrena in the United States, Canada, and Japan, and Lorviqua in the European Union, is an anti-cancer drug developed by Pfizer. It is an orally administered inhibitor of ALK and ROS1, two enzymes that play a role in the development of cancer.